Skip to Content

Tralokinumab: New treatment for atopic dermatitis

The human monoclonal antibody tralokinumab, specifically neutralizing interleukin-13, shows promising efficacy and safety in patients with atopic dermatitis in just 16 weeks. Let Professor of Dermatology Steve Feldman guide you through his take on the therapeutic potential of tralokinumab in the treatment of atopic dermatitis.

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top